Showing results (11-20 of 61) with videos related to
Sort By:
Pageof 7
Leukemia & Lymphoma|January 2, 2024
Treatment of relapsed or refractory FLT-3 acute myelogenous leukemia with a triplet regimen of hypomethylating agent, venetoclax, and gilteritinibDat Ngo, Jose Tinajero, Shanpeng Li, et al.Cancer|February 28, 2007
Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemiaAhmed Aribi, Hagop M Kantarjian, Elihu H Estey, et al.British Journal of Haematology|June 27, 2007
Biphenotypic acute leukaemia: a case seriesAhmed Aribi, Carlos Bueso-Ramos, Eli Estey, et al.British Journal of Haematology|April 1, 2024
Therapy-related acute lymphoblastic leukaemia in women with antecedent breast cancerHoda Pourhassan, Jianying Zhang, Jose Tinajero, et al.Transplantation and Cellular Therapy|May 20, 2026
High incidence of cytomegalovirus infection in patients receiving standard of care CD19- or BCMA-targeted CAR T-cell therapies for hematologic malignanciesTamer Othman, John H Baird, Yan Wang, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 7, 2009
Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasmsFarhad Ravandi, Ahmed Aribi, Susan O'Brien, et al.International Journal of Cancer|November 21, 2012
The triterpenoid cucurbitacin B augments the antiproliferative activity of chemotherapy in human breast cancerAhmed Aribi, Sigal Gery, Dhong Hyun Lee, et al.Annals of Surgery|July 13, 2026
Efficacy of Splenectomy for Hematologic Malignancies: A Retrospective Cohort StudyHamza Mohammed, Muhammad Talha Waheed, Vijay Trisal, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 1, 2020
Outcome of Allogeneic Hematopoietic Cell Transplantation after Venetoclax and Hypomethylating Agent Therapy for Acute Myelogenous LeukemiaKaramjeet S Sandhu, Sanjeet Dadwal, Dongyun Yang, et al.American Journal of Hematology|September 5, 2023
Bendamustine lymphodepletion is a well-tolerated alternative to fludarabine and cyclophosphamide lymphodepletion for axicabtagene ciloleucel therapy for aggressive B-cell lymphomaShin Yeu Ong, Stacy Pak, Matthew Mei, et al.Pageof 7